Drug Profile
BTS 79018
Alternative Names: BSF 190555Latest Information Update: 24 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antipsychotics
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 24 Jan 2013 Discontinued - Phase-I for Schizophrenia in United Kingdom (unspecified route)
- 27 Jun 2006 No development reported - Phase-I for Schizophrenia in United Kingdom (unspecified route)
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories